INTRODUCTION

Chronic migraine (CM) is defined as 15 days or more of headache per month for 3 months, including at least 8 days of migraine per month [1]. CM affects between 0.9% and 2.2% of the population [2]. Those affected score worse on both validated disability measures and quality of life assessment tools, and are subject to significant socioeconomic impact due to inability to attend social functions, work absenteeism, and substantial use of health care resources [3].

Chronic migraine is an underdiagnosed condition, with only approximately 20% of patients having received a correct diagnosis. Of those diagnosed, a significant proportion did not get appropriate migraine preventive treatment [4]. In those who are being treated, common challenges associated with oral therapy include poor tolerance, low efficacy rates among patients, and low therapeutic adherence to preventive medication [5]. These factors combined lead to failure of therapy in CM [6,7]. Before the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mABs) only topiramate [8]...
and onabotulinumtoxinA [9] had specific clinical trial data, and can-
desartan had limited data [10].

The identification of the role of CGRP in migraine [11,12] and its subsequent targeting for new therapies [13] have led to the development of treatments directed at the CGRP pathway. This has included small molecule CGRP receptor antagonists, gepants [14], and mAbs [15]. Erenumab is a CGRP mAb targeting the canonical CGRP receptor with proven efficacy in migraine prevention through randomized placebo-controlled trials (RCTs) [16–19], including data in patients with episodic migraine who have failed two to four previous preventives [18]. At the time of launch in the UK in September 2018, it had not been tested in CM patients who had failed more than two preventives [19].

**METHODS**

We audited the response of patients with CM treated with erenumab in a free-of-charge (FoC) access scheme at our tertiary headache centre at King’s College Hospital from December 2018 until December 2019. The scheme was to run until the National Institute for Health and Care Excellence released its appraisal.

**Patients**

Patients were eligible to take part in the FoC scheme if they were >18 years old (there was no upper limit for age), had CM according to the International Classification for Headache Disorders–third edition (ICHD-3) [1], and had failed to respond to at least three preventive therapies. Patients with medication overuse were not excluded.

**Dosing**

Patients were offered monthly (every 4 weeks) erenumab 70 mg sc injection for 3 months (12 weeks). If their monthly migraine days (MMD) did not improve by 50%, they were offered erenumab 140 mg sc monthly for a further 3 months. Collected data were reviewed for monthly headache days (MHD), MMD, rescue medication use days (RxD), Headache Impact Test-6 (HIT-6), Migraine Disability Assessment Scale, and adverse events (AEs).

**Outcomes**

We defined a responder in the FoC scheme as a CM patient whose MMD improved by at least 50% at Month 3 after treatment initiation compared to baseline MMD. MMD assessments were based on monthly diary data that we routinely use for clinical care. Patients who did not achieve at least a 50% migraine day reduction after 3 months of monthly 140-mg injections were considered nonresponders, and treatment was stopped. Other criteria for stopping treatment were intolerable AEs, pregnancy, patient’s choice, and noncompliance with clinical advice.

Eligible patients had the abovementioned details along with potential AEs explained before taking part in the scheme, and a consent form was signed for the treatment. The primary outcome was a comparison of MMD at the end of the month following the third injection (Weeks 8 to 12) to that of baseline (Weeks −4 to 0). We calculated the proportion of participants who had their MMD reduced by 50% and 30% over the same duration.

We compared change in MMD between participants with medication overuse and those without.

**Statistical analysis**

Monthly headache days, MMD, and RxD were treated as discrete variables (natural numbers), whereas disability scores were treated as ordinal scales and presence of aura was reported using a categorical binary scale. Median and interquartile range (IQR) were used as summary measures. Differences were examined using Mann–Whitney tests. Proportions between groups were examined using the $\chi^2$ test. Spearman rho was used to examine correlations between baseline characteristics and outcomes. Participation in the FoC scheme was fixed and limited to patients who were eligible and during the time frame while it was active. Therefore, no power calculation was performed prior to the inclusion of patients. Significant was evaluated at $p < 0.05$, with Bonferroni adjustment as appropriate. Data were analysed using IBM SPSS Statistics for Mac (v27.0). Violin plots were constructed using GraphPad Prism (v9.3.1).

**RESULTS**

**Demographics and baseline characteristics**

Ninety-two patients were started on erenumab 70 mg sc monthly injections between December 2018 and December 2019, 73 (79%) of them were females, and the median age of migraine onset was 11 years (IQR = 11–21). The patients had suffered with CM for a median of 10 years (IQR = 6–17). They had used a median of eight (IQR = 6–10) previous preventive treatments. Slightly more than half (52%, n = 48) of our patients had CM without aura, whereas 22 (24%) had CM with aura, 13 (14%) had new daily persistent headache, and the type was not available in nine (10%) patients.

Half of our cohort participants (51%, n = 47) fulfilled ICHD-3 criteria for medication overuse [1]. Forty-three patients (47%) had tried and failed to respond to onabotulinumtoxinA.

Three-month and 6-month MMD data were available for 72 and 41 patients, respectively.
Primary outcome

Baseline headache days, migraine days, analgesic use, and disability data are presented in Table 1. As expected for a tertiary headache centre, HIT-6 scores were >60. Median MMD were significantly improved at 3 (Figure 1) and 6 months (−4 days and −9 days, respectively, \( p < 0.001 \)). The MMD 30% and 50% responder rates at 3 months were 53% (n = 38) and 36% (n = 26), respectively (Table 1).

Secondary outcomes

Response at 3 months

The analysis shows that MHD, monthly analgesic days (RxD), and HIT-6 score significantly improved (Table 2 and Figures 2–4).

Of the baseline characteristics in our cohort, only the number of previous preventive classes was correlated (inversely) with improvement in MMD at 3 months (\( r_s = -0.33, p = 0.004 \); Table 3).

### Table 1
Baseline data for the audited cohort

| Outcome        | Patients, n | Median | IQR (Q1-Q3) |
|----------------|-------------|--------|-------------|
| Headache days  | 92          | 28     | 26–28       |
| Migraine days  | 92          | 15     | 10–28       |
| Analgesic days | 92          | 12     | 1–17        |
| HIT-6          | 92          | 67     | 64–71       |
| MIDAS          | 89          | 89     | 51–170      |

Abbreviations: HIT-6, Headache Impact Test-6; IQR, interquartile range; Q1, first quartile; Q3, third quartile; MIDAS, Migraine Disability Assessment Scale.

### Table 2
Outcomes at 3 months, \( n = 72 \)

| Outcome | Baseline, median, IQR (Q1-Q3) | Third month, median, IQR (Q1-Q3) | Change, median, IQR (Q1-Q3) | \( p^a \) |
|---------|--------------------------------|----------------------------------|------------------------------|--------|
| MHD     | 28, 26–28                      | 28, 16–28                        | 0, −7.0                      | <0.001*  |
| MMD     | 15, 10–28                      | 11, 4–25                         | −4, −10.0                    | <0.001*  |
| RxD     | 12, 1–17                       | 7, 2–12                          | −1, −7.0                     | <0.001*  |
| HIT-6   | 67, 64–71                      | 64, 60–68                        | −3, −7.0                     | <0.001*  |
| MIDAS   | 90, 51–170                     | 60, 23–162                       | −7, −52.22                   | 0.04    |

Abbreviations: HIT-6, Headache Impact Test-6; IQR, interquartile range; Q1, first quartile; Q3, third quartile; MHD, monthly headache days; MIDAS, Migraine Disability Assessment Scale; MMD, monthly migraine days; RxD, acute treatment days.

\(^a\) Wilcoxon signed-rank test.

\(^*\) Primary outcome.

\(^\ast\) Statistically significant: \( p < 0.01 \).
After testing assumptions for simple linear regression with a P-P plot and scatterplot, the clinical value ($r^2 = 0.106$) of that relationship is minimal.

**Figure 3** Violin plot showing shift in distribution after 3 months of treatment with erenumab in days using analgesics

**Figure 4** Violin plot showing shift in distribution after 3 months of treatment with erenumab in Headache Impact Test-6 (HIT-6) score

**Table 3** Correlation of baseline characteristics of cohort with outcome at 3 months

| Measure                      | Age | CM duration | Preventive classes, n | MHD | RxD | HIT-6 | MIDAS |
|------------------------------|-----|-------------|-----------------------|-----|-----|-------|-------|
| Spearman rho correlation coefficient | 0.166 | 0.133       | 0.04                  | 0.08 | 0.109 | 0.109 |
| Significance (two-tailed)    | 0.47 | 0.4         | 0.004                 | 0.08 | 0.30  | 0.37  |

**Abbreviations:** CM, chronic migraine; HIT-6, Headache Impact Test 6; MHD, monthly headache days; MIDAS, Migraine Disability Assessment Scale; RxD, acute treatment days.

*Correlation is significant at the 0.05 level.*
Response at 6 months

Data were available on 42 patients at 6 months; 50% (n = 21) of that cohort had their monthly erenumab escalated to 140 mg, as they did not fulfill our criteria for initial response.

The improvement in headache variables was still sustained at 6 months, and the change in disability measures was equally significant (Table 4).

Effect of medication overuse on responses at 3 months

We compared 10 baseline characteristics between the medication overuse group and the nonoveruse group. After correction for multiple comparisons, apart from RxD, the only difference was that the medication overuse group had CM for a longer period of time (Table 5).

Three-month response data were available for 72 patients, of whom 37 (51%) patients fulfilled criteria for medication overuse. There was no significant difference in the primary audit outcome, MMD change and 30% responder rate, or any of the secondary outcomes between the groups at 3 months (Table 5; Figure 5).

Adverse events

Thirty-eight (41%) patients reported AEs (Table 6). No new AEs were reported in our audit compared to what had been previously described in clinical trials and real-life data. The most common side effect reported was constipation, affecting half of those who reported AEs. Of those who reported constipation, 21% had already reported constipation prior to erenumab treatment. In total, seven (8%) patients stopped their treatment due to lack of efficacy; of them, four

**Table 4** Outcomes at 6 months, n = 42

| Outcome | Baseline, median, IQR (Q1-Q3) | Sixth month, median, IQR (Q1-Q3) | Change, median, IQR | p          |
|---------|-------------------------------|---------------------------------|---------------------|------------|
| MHD     | 28, 26-28                     | 20, 11-28                       | −5, 11-             | <0.001*a   |
| MMD     | 15, 10-28                     | 5, 2-12                         | −10, 7              | <0.001*a   |
| RxD     | 12, 1-17                      | 6, 2-8                          | −5, 6.5             | <0.001*a   |
| HIT-6   | 67, 64-71                     | 63, 58-68                       | −5, 7.5             | 0.002*a    |
| MIDAS   | 90, 51-170                    | 53, 9-106                       | −39, 72.7           | 0.004*a    |

Abbreviations: HIT-6, Headache Impact Test-6; IQR, interquartile range; Q1, first quartile; Q3, third quartile; MHD, monthly headache days; MIDAS, Migraine Disability Assessment Scale; MMD, monthly migraine days; RxD, acute treatment days.

*aStatistically significant: p < 0.01.
*bWilcoxon signed-rank test.

**Table 5** Comparison of medication overuse and nonoveruse groups

| Characteristic/outcome | Medication overuse group, n = 47, median, IQR (Q1-Q3) | Nonoveruse group, n = 45, median, IQR (Q1-Q3) | p      |
|------------------------|--------------------------------------------------------|-----------------------------------------------|--------|
| Baseline characteristics |                                                        |                                               |        |
| Sex, F:M               | 38:7                                                   | 35:12                                         | 0.24 b |
| Age                    | 47, 38 to 59                                          | 40, 29 to 52                                 | 0.007 b|
| Migraine onset         | 13, 10 to 18                                          | 14, 10 to 21                                 | 0.75 b |
| Duration of CM         | 15, 9 to 20                                           | 6, 5 to 10                                   | 0.004 b |
| Previous preventives   | 8, 7 to 10                                            | 8, 5 to 10                                   | 0.55 b |
| Baseline MHD           | 28, 22 to 28                                          | 28, 28 to 28                                 | 0.11 b |
| Baseline MMD           | 14, 10 to 23                                          | 17, 10 to 28                                 | 0.35 b |
| Baseline RxD           | 17, 15-28                                             | 2, 0-7                                       | <0.001 b |
| Baseline HIT-6         | 67, 65-70                                             | 67, 64-72                                    | 0.9 b  |
| Baseline MIDAS         | 90, 50-150                                            | 99, 52-196                                   | 0.42 b |
| Outcome at 3 months    |                                                        |                                               |        |
| n = 37                 |                                                        | n = 35                                       |        |
| MMD change             | −6, −9−1                                              | −1, −10-0                                    | 0.2 b  |
| 30% MMD; n (%)         | 23 (62)                                               | 15 (42)                                      | 0.1^a  |
| MHD change             | 0, 0-0                                                | −1, 9-0                                      | 0.2 b  |
| HIT-6 change           | −2, −5-1                                              | −5, −9-0                                     | 0.14 b |
| MIDAS change           | −18                                                   | −15                                          | 0.71 b |

Abbreviations: CM, chronic migraine; F, female; HIT-6, Headache Impact Test-6; IQR, interquartile range; M, male; MHD, monthly headache days; MIDAS, Migraine Disability Assessment Scale; MMD, monthly migraine days; RxD, acute treatment days.

*aPearson χ² test.
*bMann–Whitney test.
*p < 0.005 (corrected).
stopped the treatment after three injections, whereas three others stopped it after six injections.

No serious AEs were reported.

**DISCUSSION**

Our cohort of patients is a real-world representation of CM sufferers commonly seen in other tertiary headache centres, representing patients often excluded from RCTs for various reasons. These patients have significant disability, and a number of classes of preventive therapies have failed them. Our audit and real-world experience that has been published (Table 7) broadly support a consistent message that erenumab reduces MMD in patients with CM in whom a range of previous preventive classes have not been effective. Tolerability has been largely good, with side effects that patients accept when present given that they are usually mild and significantly outweighed...
by the efficacy benefits. These data are well reflected in a recent direct head-to-head comparison with topiramate, where both dropout rates with side effects and efficacy favoured erenumab [20]. Our clinical experience is this efficacy and side effect advantage is likely a class effect of preventives targeting the CGRP pathway.

Since its launch in 2018, there have been a number of articles discussing postmarketing clinical experience with erenumab in CM, with MHD or MMD being the main focus of the reports. Similar to previously published RCTs [19,21] and real-life data with erenumab in CM (Table 7), our data confirm the medication is effective in reducing CM burden, as proven by significant improvement in all variables used to account for disability and severity of the condition at 3 months. Importantly, the improvement at 6 months in disability measures was still significant despite the small sample size. Although MMD at baseline in our group are comparable to that of published work, half of our cohort complained of constant daily headache, yet the medication overuse rate was similar. This likely reflects cultural aspects of treatment.

At 3 months, the most pronounced change was in median MMD reduction, which became clearer at 6 months. Broadly, the data imply that a longer duration of exposure to CGRP pathway blockade may be clinically useful. More than half of our patients sustained a clinically meaningful improvement in migraine days at 3 months. The only baseline characteristics we could associate with improvement was the number of previous preventive classes, which was inversely related. However, this accounted for a small amount of variance, approximately 11%, suggesting there is little reason to preclude even the most apparently refractory patients from CGRP pathway mABs. Medication overuse of analgesics, as seen previously [22,23], does not seem to have any impact in response at 3 months.

Of AEs, constipation was prominent. Importantly, we probed for bowel habits at baseline and reviewed the same question after treatment. In general, the prevalence of constipation in real-life data is significantly higher than that published in controlled trials. Differences in constipation rate may, in part, be accounted for by baseline differences in dietary habits, with Italian studies [24] reporting a rate approximately 11%, suggesting there is little reason to preclude even the most apparently refractory patients from CGRP pathway mABs. Medication overuse of analgesics, as seen previously [22,23], does not seem to have any impact in response at 3 months.

In conclusion, our real-world data confirm the efficacy of erenumab in managing patients with CM in whom a range of previous medicines had not been useful. The new data complement previously published reports, supporting the utility of CGRP pathway mABs in preventive treatment of CM. Although several side effects were recorded in our study, there were no serious side effects, an indication of a good level of tolerability of erenumab.

CONFLICT OF INTEREST
David Moreno-Ajona, María Dolores Villar-Amrtínez and Fiona Greenwood have do not have any conflict of interest to disclose.

LIMITATIONS
our prospective analysis summarizes findings of an open-label audit; hence, nonblinding, lack of placebo or active comparator, expectation bias, and sample size would, certainly, have had an impact on our results. Our effect size is very difficult to account for. An underlying theme is the relative benefit patients ascribe to efficacy in a context of modest and tolerable side effects. Considering ongoing real-world experience is essential to optimize the use of these new medicines.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Our data availability is governed by the UK general data protection regulations.

ORCID
Modar Khalil https://orcid.org/0000-0002-7178-4725
David Moreno-Ajona https://orcid.org/0000-0002-0366-5994
Jan Hoffmann https://orcid.org/0000-0002-2103-9081
Peter J. Goadsby https://orcid.org/0000-0003-3260-5904

REFERENCES
1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.

2. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70-78.

3. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301-315.

4. Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med (Lond). 2015;15(4):344-350.

5. Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016;56:821-834.

6. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-488.

7. Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92.

8. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170-180.

9. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936.

10. Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomized, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34:523-532.

11. Goadsby PJ, et al. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193-196.

12. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187.

13. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573-582.

14. Moreno-Ajona D, et al. Gepants, calcitonin-gene related peptide (CGRP) receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33:309-315.

15. Castle D, Robertson NP. Monoclonal antibodies for migraine: an update. J Neurol. 2018;265(6):1491-1492.

16. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132.

17. Dodick DW, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-1037.

18. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280-2287.

19. Tepper SJ, et al. A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in chronic migraine prevention. Lancet Neurol. 2017;16:425-434.

20. Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611-1621.

21. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.

22. Tepper SJ, Diener H-C, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;92(20):2309-2320.

23. Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.

24. Raffaelli B, Kalantzis R, Mecklenburg J, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol. 2020;11:417.

25. Scheffler A, Messel O, Wurthmann S, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84.

26. Ranieri A, Alfieri G, Napolitano M, et al. One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci. 2020;41(2):505-506.

27. Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014-2025.

How to cite this article: Khalil M, Moreno-Ajona D, Villar-Martinez MD, Greenwood F, Hoffmann J, Goadsby PJ. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022;29:2473-2480. doi:10.1111/ene.15364